Orthocell has announced that it has completed the first commercial sales of Remplir™ in Hong Kong, representing a key milestone in the Company’s Asian growth strategy.
These initial sales follow the successful introduction of Remplir in Hong Kong, including its first surgical use and strong reception at the Hong Kong Orthopaedic Association (HKOA) 45th Annual Congress. These first sales to MontsMed provide immediate in-market availability and are expected to support multiple downstream sales as surgeons adopt the technology.
Hong Kong represents a strategically important entry point into the Guangdong–Hong Kong–Macao Greater Bay Area (GBA), one of Asia’s most dynamic healthcare regions with a population of approximately 100 million people.
Orthocell’s Chief Scientific Officer, Professor Minghao Zheng, is currently in Hong Kong delivering distributor onboarding and scientific training with the MontsMed team. This program is designed to support MontsMed’s early commercial activities by empowering clinical and sales teams to drive engagement with specialist surgeons.
Orthocell CEO and MD, Paul Anderson said:
“First Hong Kong sales represent an important commercial milestone for Orthocell and a strong validation of Remplir’s clinical value. We are well positioned to support MontsMed in driving adoption across leading hospitals in Hong Kong and the Greater Bay Area. We are executing our commercialisation strategy with discipline, and today’s achievement marks another step forward in establishing Remplir as a new standard of care in peripheral nerve repair.”